Financial Data Schedule. (Exhibit 27.1 is being submitted as an exhibit only in the electronic format of this Quarterly Report on Form 10-Q being submitted to the Securities and Exchange Commission. Exhibit 27.1 shall not be deemed filed for purposes of Section 11 of the Securities Act of 1933, Section 18 of the Securities Exchange Act of 1934 or Section 323 of the Trust Indenture Act, or otherwise be subject to the liabilities of such sections, nor shall it be deemed a part of any registration statement to which it relates.)
Financial Data Schedule. Previously Filed.
Financial Data Schedule. (1) Incorporated by reference to the indicated exhibit in Inhale's Quarterly Report on Form 10-Q for the quarter ended June 30, 1998.
Financial Data Schedule. Confidential treatment granted. 52 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Birmingham, State of Alabama, on this 28th day of March, 1997. BIOCRYST PHARMACEUTICALS, INC. BY: /S/ XXXXXXX X. XXXX ----------------------------------------- Xxxxxxx X. Xxxx, Ph.D. CHAIRMAN AND CHIEF EXECUTIVE OFFICER Pursuant to the requirements of the Securities Exchange Act of 1934 this report has been signed by the following persons in the capacities indicated on March 28th, 1997: SIGNATURE TITLE(S) - ------------------------------ --------------------------- /s/ XXXXXXX X. XXXX Chairman, Chief Executive - ------------------------------ Officer and Director (Xxxxxxx X. Xxxx, Ph.D.) /s/ J. XXXXXX XXXXXXX President, Chief Operating - ------------------------------ Officer and Director (J. Xxxxxx Xxxxxxx, M.D.) Executive Vice President, /s/ XXXX X. XXXXXXXXXX Secretary, Chief - ------------------------------ Scientific Officer and (Xxxx X. Xxxxxxxxxx, Ph.D.) Director /s/ XXXXXX X. XXXX Chief Financial Officer - ------------------------------ (Principal Financial and (Xxxxxx X. Xxxx) Accounting Officer) /s/ XXXXXXX X. XXXXXXXXXXXXX Director - ------------------------------ (Xxxxxxx X. Xxxxxxxxxxxxx) /s/ XXXXX X. XXX Director - ------------------------------ (Xxxxx X. Xxx, Ph.D.) /s/ XXXX X. XXXXXXXX Director - ------------------------------ (Xxxx X. Xxxxxxxx, Ph.D.) SIGNATURE TITLE(S) - ------------------------------ --------------------------- /s/ XXXXXXX X. XXXXXXXXX Director - ------------------------------ (Xxxxxxx X. Xxxxxxxxx, M.D.) /s/ XXXXXXX X. XXXXXXX, III Director - ------------------------------ (Xxxxxxx X. Xxxxxxx, III) /s/ XXXXXX X. XXXXXXXX, XX. Director - ------------------------------ (Xxxxxx X. Xxxxxxxx, Xx.) /s/ XXXXXXXX X. XXXXX Director - ------------------------------ (Xxxxxxxx X. Xxxxx, M.D., Ph.D.) INDEX TO EXHIBITS SEQUENTIALLY NUMBERED NUMBER DESCRIPTION PAGE -
Financial Data Schedule. Confidential treatment granted. 56 EXHIBIT 10.11 BIOCRYST PHARMACEUTICALS, INC. 0000 Xxxxxxx Xxxx Xxxxx Xxxxxxxxxx, Xxxxxxx 00000 December 17, l996
Financial Data Schedule. Not less than three (3) Business Days prior to the Closing Date, the Seller shall deliver to Purchaser, certified by an executive officer of the Seller, a financial data schedule prepared on a basis consistent with the practices used in preparing the Reference Balance Sheet, presenting the Seller’s good faith estimate of (i) the Net Working Capital as of the Closing Date (“Estimated Closing Net Working Capital”) and (ii) the Cash Balance as of the Closing Date (the “Estimated Cash Balance”).
Financial Data Schedule. E-23 -------------------------
Financial Data Schedule. (1) Previously filed as Exhibit 3.2 to our Registration Statement on Form S-1, Registration No. 333-33016.
